Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Fig. 2

Association between rs822336 and clinical outcomes in advanced NSCLC patients treated with pembrolizumab plus platinum-based chemotherapy. PFS (A) and OS (B) of NSCLC patients treated with anti-PD-1 pembrolizumab plus platinum-based chemotherapy were stratified based on PD-L1 rs822336 genotypes. PFS and OS were compared using the Kaplan-Meier method. Differences in patients’ survival were analyzed using a log-rang test. P < 0.05 was considered statistically significant

Back to article page

Molecular Cancer

ISSN: 1476-4598